Loading clinical trials...
Loading clinical trials...
A Phase 3b Multi-center, Open Label, Single Arm, 52-week Study, Evaluating the Feasibility, Efficacy and Safety of Rapid Test and Treat Intervention in Newly Diagnosed HIV-1 Infected Adults Using a Fixed Dose Combination of Dolutegravir Plus Lamivudine (DOVATO) as a First Line Regimen
Conditions
Interventions
Dolutegravir + Lamivudine FDC
Locations
16
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Los Angeles, California, United States
GSK Investigational Site
Palm Springs, California, United States
GSK Investigational Site
Ft. Pierce, Florida, United States
GSK Investigational Site
Miami, Florida, United States
GSK Investigational Site
Oakland Park, Florida, United States
Start Date
July 2, 2019
Primary Completion Date
April 29, 2020
Completion Date
October 20, 2020
Last Updated
October 21, 2021
NCT06627764
NCT06694805
NCT04142047
NCT05398185
NCT07428330
NCT07225530
Lead Sponsor
ViiV Healthcare
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions